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PROTAMINE was first used in the treatment of malignant disease by O'Meara
and O'Halloran (1963) andHughes (1964). In a small seriesofcases they reported
that changes occurredin over halfthe patientstreated, malignant massesbecoming
smaller and more mobile, and malignant ulcers re-epithelialising. This larger
clinical trial was undertaken to confirm their results, and to assess the value of
protamine as a cancer chemotherapeutic agent.
MATERLALS AND METHODS
The protamine used in this trial was Clupeine prepared from herring roes. It
is inactive if given orally, and must therefore be used parenterally. Protamine
itself as the salt yields a strongly acidic solution unsuitable for use over long
periods. Three other forms were available. Prolothan G is a 10% solution of
protamine in 40 % glucose, brought to neutrality. It is the most potent form
available, being fully active as measured by heparin titration. However, it is
still too irritative for intramuscular use and was given in doses of 1-2 g. daily
(10-20c.c.)dilutedin 11. ofnormalsalinebyslowintravenousinfusion. ProlothanA
is a 10 % solution of protamine formaldehyde bi-sulphite. It has no activity as
measured by heparin titration, but is thought to break down in the body to yield
active protamine. It was administered in doses of 2 g. daily (20 c.c.) by deep
intramuscular injection in divided doses. The third form was a cream containing
10 % protamine in a lanolin base.
Case selection
A total of 56 cases was treated. With few exceptions these were either
unsuitable for treatment by conventional methods of had failed to respond to
previous therapy. Terminal patients were excluded. Only cases where the
tumour mass or ulcer was measurable directly or by radiography were accepted.
Afew cases with specific symptoms were also accepted where subjective assessment
was possible. Histological proofofdiagnosis was obtained in all but one case. In
this instance clinical diagnosis was thought to be incontrovertible.
Scheme of treatment
Seventeen cases with malignant ulcers were treated with protamine cream.
This was applied twice daily for a minimum of 1 month. The size ofthe ulcer was
measuredweekly. Thirty-nine caseswith solidtumours weretreated. Twenty-one
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ofthese were treated with twicedailyProlothanA. Afurther 19 cases weregiven a
course of Prolothan G intravenously over several days, treatment then being
maintained with Prolothan A intramuscularly. Treatment was withdrawn if it
became apparent that the tumour was progressing, or ifside effects became severe.
Tumour size was measured daily initially, and weekly after the first month. In
addition changes in tumour consistence and mobility were also noted. Routine
blood counts, clotting functions, serum electrolytes, serum calcium, and urine
examinations were also performed.
RESULTS
The results of treatment with protamine cream in the 17 cases with ulcerated
lesions are shown in Table I. Only one case improved. A rodent ulcer showed
TABLE I.-Results ofTreatment of Ulcerated Lesions with Protamine Cream
Duration of Results
Number Biopsy treatment in __ _
Type of Ulcer of cases proven weeks No change Improved Worse
Rodent 5 . 5 12, 16, 7, 9,. 2 1 2
4,
Epithelioma . 2 2 8, 4, . 2
Primary breast carcinoma . 3 . 2 8, 12, 12, . 1 2
Skin metastases from . 5 . 5 . 14, 8, 10, . 3 2
carcinoma of breast . 4, 8,
Perineal recurrence from 1 . 1 . 17, . 1
carcinoma of rectum
Ulcerated gland of neck from 1 . 1 . 6, . 1
carcinoma of tongue
Totals 17 16 . 6 1 10
50 % re-epithelialization after 6 weeks. Continued treatment failed to reduce it
further in size and it was therefore excised. Two patients showed evidence of
sensitivity, the surrounding skin becoming red and sore. It was not effective in
removing sloughs or reducing odour.
Thirty-nine patients representing 22 different types ofmalignant disease were
treated with parenteral protamine. The results are shown in Table II. Three
cases, No. 3, 20, 29, received only short courses oftreatment for the reasons shown
in Table II. They are included in order to demonstrate some of the side effects
found. Five patients showed definiteimprovement. They are recorded in greater
details.
Case 2.-Mrs. L. B., aged 69, first noticed a lump in her neck 21 years before
treatment. This had recently grown much larger. When first seen there was a
hard fixed mass replacing the left lobe of the thyroid, contiguous with a mass of
fixed glands extending into the posterior triangle. Biopsy showed the mass to be
a papillary thyroid carcinoma. It was deemed to be inoperable and was treated
with a course ofradiotherapy 5300 r. being given over 6 weeks. Towards the end
of this course, the mass became larger, and tumour fungated through the skin
over an area of 4 X 3 cm. Tumour size at this time was 13 x 7 cm. Prolothan
was commenced 1 weekfollowing the lastdose ofradiation. Bythefourteenth day
the ulcerated area was only 1 cm. diameter, and the tumour, though no smaller,
was more mobile. Prolothan A was given for 6 months. The ulcerated area
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healed entirely at the end of the third month. At the end of the course the
tumour was much smaller, 10 x 5 cm. Further treatment was refused due to
marked local reaction at injection sites. She has remained well, and the tumour
has shown no change over the last 2 years.
Case 8.-Mr. A. P., aged 45. A malignant melanoma had been removed from
his left thigh 4yearsbefore. Severalscatteredcutaneousandglandularrecurrences
had been excised since then. On admission to the trial he had multiple (over
100) cutaneous nodules of varying size, which were growing rapidly. After 14
days' treatment many of the nodules had decreased in size by as much as 50 %.
One such nodule was excised and proved to be entirely necrotic. The nodules
showed no further change in size for 4 months, during which time Prolothan A was
given continuously. They then began to grow again. A second course of
Prolothan G was given without effect. He died 2 months later.
Case 9.-Mrs. M. B., aged 62. A right nephrectomy had been performed 3
months previously for renal carcinoma. Two weeks before her admission to the
trial she had developed a severe cough with haemoptysis and chest pain. Chest
X-ray showed multiple round pulmonary secondaries. At the end of 3 weeks she
had lost all her symptoms and was able to return home, and even go away on
holiday. However, her chest x-ray showed no change. She continued on treat-
mentfornearly 3 months, dyingwithmassive liverdeposits while still onProlothan.
Her cough and haemoptyses did not return.
Case 17.-Mrs. C. L., aged 59. Three years previously a chondrosarcoma of
the right ischium had been treated with radiotherapy, 5700 r. being given. One
month before the commencement of Prolothan she had developed severe pain in
the right hip and knee, together with numbness, and loss of sensation over the
inner side of the right thigh, in the distribution of the obturator nerve. She was
confined to bed, andunable towalk morethan afew steps because ofthe pain. She
received Prolothan for 1 month. By the end of this time she had lost nearly all
her pain and was able to walk up to a quarter of a mile. She remained well 18
months later.
Case 34.-Mrs. A. B., aged 60. A partial gastrectomy had been performed 1
year before for carcinoma of the stomach. She was re-admitted with severe pain
in the left chest of 1 month's duration. Examination showed 7 small cutaneous
nodules over the left chest, with 2 tender expanded ribs. x-ray confirmed the
presence ofrib metastases. She was given a 4 weeks' coure ofProlothan A. By
the end of this time all the nodules had reduced in size by one third. The pain
was much reduced, no longer needing pethidine forrelief. However, the injections
caused so much local reaction that further treatment was refused. She died 3
months later.
Side effects
Side effects were commonly seen. All patients given Prolothan G experienced
nausea or vomiting. This was difficult to control with the usual anti-nausea drugs.
Severe phlebitis at infusion sites was seen, often occurring within 24 hours. For
this reason long cannulas were used passed into the subelavian vein. One side
effect was unexpected. Prolothan G was found to depress the level of serum
calcium in all patients. In 3 cases (1, 3, 26) overt tetany occurred. This effect
is thought to be due to neutralisation of heparin, which is involved in bone
resorption and deposition. Prolothan A which is not active againstheparin has no
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such effect on serum calcium. This side effect has been reported in more detail
(Anderson, Tomlinson and Wright (1967)).
With Prolothan A, tenderness and swelling at the site of injection occurred in
all patients. This was always troublesome and in 4 cases led to further treatment
being refused. In 3 cases sterile abscesses appeared and one required incision
and drainage. There was no depression ofthe haemoglobin level nor of the white
blood cell count. No evidence was found to suggest gross alteration in the blood
clotting system either clinically or haematologically. No attempt was made
however to estimate serum heparin levels, which were presumably reduced.
DISCUSSION
O'Meara and Thornes (1961) reported the isolation of a labile protein fraction
from cancer tissue which they claimed was responsible for the deposition of
fibrin on advancing tumour cells. They called this protein the cancer coagulative
factor and claimed it was essential for tumour growth. Thornes and O'Meara
(1961) showed that protamine neutralised this factor and Thornes and Martin
(1961) using Hela cell mono-layers showed protamine to have both growth arresting
and cyto-pathic effects. These effects were confirmed in experimental mice
tumours (Muggleton, MacLaren and Dyke, 1964). The first reported clinical
trials of O'Meara and O'Halloran (1963) and Hughes (1964) showed reduction in
size and increase in mobility in 50 % of the tumours treated. However, only small
numbers were involved, and the therapy was continued for only a short period.
In view of their promising results, and since protamine had none of the disadvan-
tages associated with the cytotoxic/anti-metabolite group ofdrugs, it was felt that
a longer trial was justified.
The present results are not encouraging. Prolothan cream was not successful
in re-epithelialising a single malignant ulcer, nor was it effective in clearing away
sloughs. It is concluded that it is no more effective than the more commonly
used applications. Parenteral protamine produced useful changes in 5 out of 39
cases of solid tumour, i.e. 13 %. Only 2 of these cases were benefited for more
than 6 months. However, both these patients are alive and well more than 2
years later. Although Prolothan A is less potent than Prolothan G as judged by
heparin neutralisation, it appears to be as effective as an anti-cancer agent.
Tumour changes appear slowly, and since Prolothan G can be given for only a
week or so, it is probably of limited value. Prolothan A, however, caused much
discomfort, possibly as much or more than it relieved. By treating a wide
spectrum of cases, it was hoped to deduce which type of cancer would respond
best. No such pattern emerged.
It is concluded that the protamine derivatives at present available have little
to offer. Should more acceptable forms become available, perhaps a further trial
would be indicated.
SUMMARY
A total of 56 patients with malignant disease were treated with preparations
of protamine. Only 1 out of 17 patients with malignant ulcers derived benefit
from protamine cream. Using parenteral protamine 5 out of 39 cases (13 %) with
solid tumours showed improveinent. In view of its unpleasant side effects, it is
felt that the present preparations are of limited value.
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This work was done during the tenure ofan Evans Medical Research Fellowship
in the Department of Surgery, King's College Hospital Medical School, under
Professor J. G. Murray.
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